SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Michelsen B.)
 

Sökning: WFRF:(Michelsen B.) > One-Year Treatment ...

  • Glintborg, B.University of Copenhagen (författare)

One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-03-08
  • Wiley,2022

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/315575
  • https://gup.ub.gu.se/publication/315575URI
  • https://doi.org/10.1002/acr.24523DOI
  • https://lup.lub.lu.se/record/efaeb55e-dfe7-46ea-8366-6358bd48644dURI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:148958620URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Objective To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA) using adalimumab as the main comparator. Methods This was an observational, prospective cohort study. Patients with SpA (clinical ankylosing spondylitis, nonradiographic axial SpA, or undifferentiated SpA) starting secukinumab or a TNFi during 2015-2018 were identified from 5 Nordic clinical rheumatology registries. Data on comorbidities and extraarticular manifestations (psoriasis, uveitis, and inflammatory bowel disease) were captured from national registries (data available in 94% of patients) and included in multivariable analyses. We assessed 1-year treatment retention (crude survival curves, adjusted hazard ratios [HRadj] for treatment discontinuation) and 6-month response rates (Ankylosing Spondylitis Disease Activity Score [ASDAS] score <2.1, Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] <40 mm, crude/LUNDEX-adjusted, adjusted logistic regression analyses with odds ratios [ORs]) stratified by line of biologic treatment (first, second, and third plus). Results In total, 10,853 treatment courses (842 secukinumab and 10,011 TNFi, of which 1,977 were adalimumab) were included. The proportions of patients treated with secukinumab during the first, second, and third-plus lines of treatment were 1%, 6%, and 22%, respectively). Extraarticular manifestations varied across treatments, while other baseline characteristics were largely similar. Secukinumab had a 1-year retention comparable to adalimumab as a first or second line of treatment but poorer as a third-plus line of therapy (secukinumab 56% [95% confidence interval (95% CI) 51-61%] versus adalimumab 70% [95% CI 64-75%]; HRadj 1.43 [95% CI 1.12-1.81]). Across treatment lines, secukinumab had poorer estimates for 6-month response rates than adalimumab, statistically significantly only for the third-plus line (adjusted analyses: ASDAS score <2.1 OR 0.56 [95% CI 0.35-0.90]; BASDAI <40 mm OR 0.62 [95% CI 0.41-0.95]). Treatment outcomes varied across the 5 TNFi. Conclusion Secukinumab was mainly used in biologics-experienced patients with SpA. Secukinumab and adalimumab performed similarly in patients who had failed a first biologic, although with increasing prior biologic exposure, adalimumab was superior.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Lindström, UlfGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Sahlgrenska Academy(Swepub:gu)xlulfn (författare)
  • Di Giuseppe, D.Karolinska Institutet,Karolinska Institute (författare)
  • Provan, S. A.Diakonhjemmet Hospital (författare)
  • Gudbjornsson, B.University of Iceland (författare)
  • Hetland, M. L.University of Copenhagen (författare)
  • Michelsen, B.Diakonhjemmet Hospital (författare)
  • Wallman, Johan K.Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-jnk (författare)
  • Aaltonen, K. (författare)
  • Hokkanen, A. M.Helsinki University Central Hospital (författare)
  • Nordstrom, D.Helsinki University Central Hospital (författare)
  • Jorgensen, T. S.Copenhagen University Hospital (författare)
  • Hansen, R. L.Copenhagen University Hospital (författare)
  • Geirsson, A. J.Karolinska Institutet,Karolinska Institute (författare)
  • Gron, K. L.Copenhagen University Hospital (författare)
  • Krogh, N. S. (författare)
  • Askling, J. (författare)
  • Kristensen, L. E.Copenhagen University Hospital (författare)
  • Jacobsson, Lennart T. H.,1954Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Sahlgrenska Academy(Swepub:gu)xjacle (författare)
  • University of CopenhagenInstitutionen för medicin, avdelningen för reumatologi och inflammationsforskning (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Arthritis Care & Research: Wiley74:5, s. 748-7582151-464X2151-4658

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy